ClinicalTrials.Veeva

Menu

Autonomic and Cardiovascular Recovery After the Acute Use of Resveratrol in Overweight and Obesity Individuals

T

Taisy Cinthia Ferro Cavalcante

Status

Enrolling

Conditions

Cardiovascular Diseases
Autonomic Nervous System
Polyphenols

Treatments

Dietary Supplement: Resveratrol Experimental

Study type

Interventional

Funder types

Other

Identifiers

NCT06020313
5.051.852

Details and patient eligibility

About

The aim of this study is to understand the importance of resveratrol supplementation as a possible adjuvant in improving the metabolic profile and cardiovascular autonomic recovery of individuals with overweight and grade I obesity, reducing the incidence of diseases associated with obesity and the costs in primary, secondary and tertiary care.

Full description

Food is a strong ally in improving the metabolic state in overweight, obesity and prevention of associated diseases, working on weight loss and ingestion of anti-inflammatory, anti-oxidant and cardioprotective substances, among these substances, we highlight the polyphenols. Resveratrol or 3,5,4-trihydroxystilbene is a polyphenol studied since 1976, a phytoalexin synthesized in the skin of the grape, which is increased when exposed to stresses such as ultraviolet radiation, enhancing the antioxidant and cardioprotective characteristics.This study aims to evaluate the cardiovascular autonomic recovery and the metabolic profile with the acute effect of resveratrol extract after submaximal aerobic exercises in individuals with overweight and grade I obesity.Heart rate variation (HRV) is considered the most trivial method for analyzing the behavior of autonomic efferents (parasympathetic and sympathetic) on the heart. HRV recovery after exercise has been widely used as a method of analyzing ANS adaptation (vagal recovery) under various conditions.Healthy, physically active individuals with good health characteristics have a rapid recovery of HRV after exercise, indicating good adaptability and a lower risk for cardiovascular diseases. Meanwhile, changes HRV patterns provide a sensitive and early indicator of health impairments. The monitoring of these data is necessary, as they act as markers of emerging risk for the development of complications associated with CNCDs and risks of future injuries. In this context, the present project will make it possible to verify the effect of the acute use of resveratrol on the metabolic profile and on the autonomic and cardiovascular recovery of individuals with overweight and obesity grade I.

Enrollment

30 estimated patients

Sex

All

Ages

20 to 59 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Individuals with overweight and obesity grade I

Exclusion criteria

  • Cardiorespiratory disorders
  • Neurological disorders
  • skeletal muscle injury
  • Known impairments that prevent the subject from performing the procedures.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

30 participants in 2 patient groups, including a placebo group

Experimental Resveratrol
Experimental group
Description:
Resveratrol capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
Treatment:
Dietary Supplement: Resveratrol Experimental
Placebo
Placebo Comparator group
Description:
After 48h washout, placebo capsules (100mg) will be used from 7am to 7pm, de 3 em 3h. That is, at 7 am, 10 am, 1 pm, 4 pm and 7 pm for 7 days.
Treatment:
Dietary Supplement: Resveratrol Experimental

Trial contacts and locations

1

Loading...

Central trial contact

Taisy Ferro Cavalcante, Dr; Taisy Ferro Cavalcante, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems